References
- Baldoni D, Bruderer S, Krause A, et al. (2014). A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial. Clin Drug Investig 34:807–18.
- Caroff E, Hubler F, Meyer E, et al. (2015). 4-((R)-2-{[6-((S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic acid butyl ester (ACT-246475) and its prodrug (ACT-281959), a novel P2Y 12 receptor antagonist with a wider therapeutic window in the rat than clopidogrel. J Med Chem 58:9133–53.
- ClinicalTrials.gov. (2018a). A medical research study to evaluate the effects of ACT-246475 in adults with coronary artery disease – NCT03384966. Available from: https://clinicaltrials.gov/ct2/show/NCT03384966?term=NCT03384966&rank=1 [last accessed 17 Apr 2019].
- ClinicalTrials.gov. (2018b). A medical research study to evaluate the effects of ACT-246475 in adults with heart attack – NCT03487445. Available from: https://clinicaltrials.gov/ct2/show/NCT03487445?term=NCT03487445&rank=1 [last accessed 17 Apr 2019].
- ClinicalTrials.gov. (2018c). A study to evaluate ACT-246475 fate in healthy male subjects – NCT03593278. Available from: https://clinicaltrials.gov/ct2/show/NCT03593278?term=NCT03593278&rank=1 [last accessed 17 Apr 2019].
- European Medicines Agency. (2012). Guideline on the investigation of drug interactions.
- Fleck C, Bräunlich H. (1990). Factors determining the relationship between renal and hepatic excretion of xenobiotics. Arzneimittelforschung 40:942–6.
- Floyd CN, Passacquale G, Ferro A. (2012). Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet 51:429–42.
- Food and Drug Administration. (2016). Guidance for industry safety testing of drug metabolites guidance for industry.
- Food and Drug Administration. (2017). Guidance for industry in vitro metabolism- and transporter-mediated drug–drug interaction studies.
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13.
- ICRP. (2007). Radiological protection in biomedical research. ICRP Publication 103, Ann ICRP.
- Jedlitschky G, Hoffmann U, Kroemer HK. (2006). Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2:351–66.
- Juif PE, Boehler M, Dobrow M, et al. (2019). Clinical pharmacology of the reversible and potent P2Y12 receptor antagonist ACT-246475 after single subcutaneous administration in healthy male subjects. J Clin Pharmacol 59:123–30.
- Mao L, Jian C, Changzhi L, et al. (2013). Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis 106:517–27.
- Obaidat A, Roth M, Hagenbuch B. (2012). The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52:135–51.
- O’Connor SA, Hulot J-S, Silvain J, et al. (2012). Pharmacogenetics of clopidogrel. Curr Pharm Des 18:5309–27.
- Rey M, Kramberg M, Hess P, et al. (2017). The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat. Pharmacol Res Perspect 5:e00338–11.
- Roffey SJ, Obach RS, Gedge JI, et al. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43.
- Sawada T, Shinke T, Shite J, et al. (2011). Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 75:99–105.
- Sibbing D, Stegherr J, Latz W, et al. (2009). Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30:916–22.